Biotron Drug Shows 85% Inhibition Against Hepatitis Delta in Lab Study
Biotron expands BIT-HBV001’s treatment potential with Hepatitis Delta breakthrough
Biotron Limited has reported that its lead drug candidate BIT-HBV001 demonstrates antiviral activity against Hepatitis Delta Virus (HDV), significantly expanding the compound’s addressable market beyond standalone Hepatitis B treatment. Laboratory studies conducted at SCRIPPS Institute in San Diego showed the drug inhibited HDAg production (a marker of HDV infection) by approximately 85% compared to untreated controls in cells co-infected with both viruses.
The Biotron BIT-HBV001 Hepatitis Delta discovery is material for investors because HDV represents the most severe form of viral hepatitis, affecting an estimated 12-60 million people globally. HDV is classified as a satellite virus, meaning it only infects individuals already carrying Hepatitis B Virus (HBV). Co-infection with both viruses is associated with rapid progression to cirrhosis, liver failure, and hepatocellular carcinoma, creating a high-severity patient population with limited treatment options.
The finding positions BIT-HBV001 as a potential component of “functional-cure” therapies targeting both HBV and its most aggressive co-infection variant. This broadens the commercial opportunity for Biotron’s lead asset and differentiates it within a competitive hepatitis development landscape.
Managing Director outlines functional-cure pathway
Michelle Miller, Managing Director
“This latest finding that BIT-HBV001 also targets HDV opens up additional treatment pathways for serious HBV infection in a population that is in need of effective treatment strategies. Inhibition of HDAg production in HBV/HDV co-infected cells supports the continued development of BIT-HBV001 as a candidate component of future ‘functional-cure’ therapies for HBV infection.”
Miller’s commentary emphasises the strategic significance of addressing HDV co-infection, which represents the hardest-to-treat segment of the hepatitis market. Functional-cure therapies aim to stop persistent viral infection rather than merely managing symptoms, positioning BIT-HBV001 within a high-value therapeutic category.
When big ASX news breaks, our subscribers know first
Understanding Hepatitis Delta (the most severe form of viral hepatitis)
Hepatitis Delta Virus requires explanation for retail investors unfamiliar with viral hepatitis taxonomy. HDV is a defective virus that cannot replicate on its own. It requires the presence of Hepatitis B Virus to complete its life cycle, making it exclusively a co-infection risk for individuals already carrying HBV.
The clinical significance lies in disease severity. Patients co-infected with HBV and HDV experience the most aggressive form of viral hepatitis, with rapid progression to life-threatening liver complications. Current treatment options remain limited, creating a significant unmet medical need that commands regulatory attention and premium pricing for successful therapies.
Key facts about Hepatitis Delta Virus:
- Satellite virus requiring HBV co-infection to replicate
- Estimated 12-60 million people infected globally
- Associated with most severe hepatitis outcomes (cirrhosis, liver failure, hepatocellular carcinoma)
- Limited current treatment options available
- Represents highest-severity patient segment within hepatitis market
The patient population affected by HDV co-infection is smaller than the standalone HBV market but carries higher clinical urgency. This positions BIT-HBV001’s activity against both viruses as a potential differentiator in future commercialisation discussions.
The broader HBV opportunity and BIT-HBV001’s development pathway
The company has previously reported that BIT-HBV001 demonstrated strong antiviral activity against Hepatitis B Virus in cell-based assays, with that activity confirmed in two animal models of hepatitis liver diseases and infection. The HDV finding extends this preclinical validation into co-infection scenarios.
Chronic HBV infection leads to complications such as cirrhosis and liver cancer, which cause close to one million deaths worldwide each year. Over 2 billion people globally have been infected with HBV at some point, and the World Health Organisation estimates that over 250 million remain chronically infected. The company states there remains an unmet need for HBV cure therapies that stop persistent viral infection rather than merely suppressing viral load.
| Metric | Figure |
|---|---|
| Global HBV infections (lifetime) | 2+ billion |
| Chronic HBV infections | 250+ million |
| Annual HBV-related deaths | ~1 million |
| HDV co-infections (estimated) | 12-60 million |
| BIT-HBV001 HDV inhibition (study result) | ~85% |
The market opportunity combines a large base of chronic HBV patients with a high-severity subset suffering HDV co-infection. Successful therapies addressing both populations could command differentiated commercial positioning, particularly if they contribute to functional-cure regimens that eliminate the need for lifelong antiviral therapy.
Sedarex integration complete as Biotron advances dual-asset strategy
Biotron completed its acquisition of Sedarex Limited in December 2025, adding the next-generation general anaesthetic SedRx to its pipeline. The company reports that integration of Sedarex is now complete from both corporate and operational perspectives, positioning Biotron as a two-asset development company.
The company is working with an international regulatory advisory group to prepare a submission to the European Medicines Agency (EMA) requesting scientific advice on the European regulatory pathway for SedRx. Good progress is being made, and Biotron expects to receive formal guidance before the 31 July 2026 deadline established under the acquisition agreement terms.
In parallel, the company and its regulatory advisors are exploring accelerated regulatory pathways for SedRx in the United States.
Upcoming SedRx regulatory milestones:
- EMA scientific advice submission in progress
- Formal European guidance expected before 31 July 2026
- US accelerated pathways under review
The dual-asset strategy provides investors with multiple catalyst opportunities across different therapeutic areas. Near-term regulatory milestones for SedRx complement ongoing preclinical development of BIT-HBV001, diversifying the company’s commercial timeline risk.
The next major ASX story will hit our subscribers first
What’s next for Biotron investors
Biotron has scheduled an investor webinar for Thursday 19 March 2026 at 10:30am AEDT to discuss the HDV findings and provide updates on both development programs. Investors can register using this link: https://us06web.zoom.us/webinar/register/WN_zrS05KJdR-CFUET4tJQabg. Participants may submit questions at registration or during the live session.
Near-term catalysts for investors include progression of BIT-HBV001 through further preclinical validation studies and receipt of EMA scientific advice on SedRx’s European regulatory pathway. The HDV activity data strengthens the scientific rationale for BIT-HBV001’s continued development as a component of functional-cure therapies, potentially attracting partnership interest from larger pharmaceutical companies seeking hepatitis assets.
The webinar provides a direct engagement opportunity for retail investors to hear from management and submit questions on development timelines, regulatory strategy, and commercial planning for both assets. With regulatory guidance expected for SedRx within four months and ongoing BIT-HBV001 studies, the company enters a catalyst-rich period across its dual-asset portfolio.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive biotech updates the moment market-moving announcements hit the ASX, with expert coverage already done for you.